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Background: The aim of this study was to evaluate the clinical outcome after seven-day artesunate monotherapy
for uncomplicated Plasmodium falciparum malaria in Yingjiang County along the China-Myanmar border and
investigate genetic polymorphisms in the P. falciparum chloroquine-resistance transporter (pfcrt), multidrug
resistance 1 (pfmdr1), dihydrofolate reductase (pfdhfr), dihydropteroate synthase (pfdhps) and ATPase (pfatp6) genes.
Methods: Patients≥ one year of age with fever (axillary temperature ≥37.5°C) or history of fever and P. falciparum
mono-infection were included. Patients received anti-malarial treatment with artesunate (total dose of 16 mg/kg
over seven days) by directly observed therapy. After a 28-day follow-up, treatment efficacy and effectiveness were
assessed based on clinical and parasitological outcomes. Treatment failure was defined as recrudescence of the
original parasite and distinguished with new infection confirmed by PCR. Analysis of gene mutation and
amplification were performed by nested polymerase chain reaction.
Results: Sixty-five patients were enrolled; 10 withdrew from the study, and six were lost to follow-up. All but two
patients demonstrated adequate clinical and parasitological response; 12 had detectable parasitaemia on day 3.
These two patients were confirmed to be new infection by PCR. The efficacy of artesunate was 95.9%. The pfcrt
mutation in codon 76 was found in all isolates (100%), and mutations in codons 71 and 72 were found in 4.8% of
parasite isolates. No mutation of pfmdr1 (codons 86 or 1246) was found. Among all samples, 5.1% were wild type
for pfdhfr, whereas the other samples had mutations in four codons (51, 59, 108 and 164), and mutations in pfdhps
(codons 436, 437, 540 and 581) were found in all isolates. No samples had mutations in pfatp6 codons 623 or 769,
but two new mutations (N683K and R756K) were found in 4.6% and 9.2% of parasite isolates, respectively.
Conclusion: Plasmodium falciparum infection was associated with slow parasite clearance and suspected
artemisinin resistance at the China-Myanmar border area. The prevalence of pfcrt 76 T and markers for SP resistance
are still high. It should be strengthened further on parasite clearance time or clearance half life to confirm the
resistance status, and molecular epidemiology should provide complementary information to assess the
appropriateness of current policies based on artemisinin derivatives.
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Malaria is a severe infectious disease, and drug resist-
ance to anti-malarial drugs is a major public health
problem worldwide [1]. In the last five years, there has
been increasing concern about the emergence of resist-
ance to artemisinin anti-malarials in Southeast Asia [2].
Several publications, including WHO reports, have pro-
vided evidence for the presence of Plasmodium falciparum
tolerance/resistance to artesunate in populations on the
Cambodia-Thailand border [3,4].
Falciparum malaria is now found in only two provinces
in China: Yunnan province, which borders Myanmar,
Laos and Vietnam, and Hainan province. Malaria control
measures have been actively implemented in this area
for more than 30 years with considerable success, and
there are no local falciparum malaria cases in Hainan
[5]. However, the malaria situation at the China-
Myanmar border remains serious.
China was the first country to use artemisinins, but
their wide-scale use in China began only in the early
1990s. The standard treatment regimen was 12 mg/kg
artesunate or artemether over five days, which continued
to be widely used until 2007. Since 2001, the WHO has
recommended the use of artemisinin-based combination
therapy in all areas where P. falciparum is resistant to
other anti-malarial medicines to optimize therapeutic ef-
fectiveness and delay the emergence of resistance. In
2006, the WHO advocated a complete ban on artemisi-
nin monotherapy for uncomplicated malaria [6]. The na-
tional drug policy of China was updated in 2009, and
since then, the first-line drugs used to treat falciparum
malaria has been artemisinin-based combination therapy
(ACT), which includes dihydroartemisinin-piperaquine,
artesunate-amodiaquine, artimisinin-naphthoquine phos-
phate and artemisinin-piperaquine [7].
Until now, ACT has been the only effective treatment
for falciparum malaria. At a time when ACT is being
rolled out in endemic malaria areas all over the world
and is beginning to have an effect on morbidity and
mortality in tropical Africa, the development and spread
of ACT resistance would have grave consequences for
global malarial control. Because of these concerns, na-
tional malaria programmes conduct systematic periodic
in vivo malaria therapeutic efficacy studies in sentinel
sites to monitor P. falciparum and Plasmodium vivax
sensitivity to first-line, anti-malarial treatments.
Several genetic polymorphisms that can provide reli-
able data about the prevalence of drug resistance have
been described in P. falciparum and P. vivax. The most
relevant polymorphisms are presented below. The 76 T
allele in the chloroquine-resistance transporter gene
(pfcrt) is predictive of chloroquine and amodiaquine
treatment failure [8–10]. The 86Y allele of the multidrug
resistance gene 1 (pfmdr1) has been linked tochloroquine and amodiaquine resistance, and increased
chloroquine inhibitory concentrations in P. falciparum
have been linked with pfcrt 76 T [11]. The triple dihydro-
folate reductase (pfdhfr) haplotype N51I/C59R/S108N
has been associated with sulphadoxine-pyrimethamine
(SP) treatment failure, and the addition of the dihydrop-
teroate synthase (pfdhps) SNPs G437A and K540E pro-
duces highly resistant P. falciparum [12–16]. The sarco/
endoplasmic reticulum Ca2+-ATPase ortholog of P. fal-
ciparum (pfatp6) was suggested to be involved in the
mechanism of action and resistance of the parasite to
artemisinins [17].
The aim of this study was to evaluate clinical outcome
after seven-day artesunate monotherapy for uncompli-
cated P. falciparum malaria in Yingjiang County along
the China-Myanmar border and to investigate the preva-
lence of genetic polymorphisms in pfcrt, pfmdr1, pfdhfr,
pfdhps and pfatp6.
Methods
Study sites and design
The study was a one-arm prospective evaluation of clin-
ical and parasitological response to directly observe
treatment for uncomplicated malaria. The study was
conducted in Yingjiang County, which is near Lazan City
in Myanmar.
Recruitment of patients
Patients over six months of age with fever (axillary
temperature ≥37.5°C) or history of fever in the previous
48 hours were included. The included patients had
mono-infection with P. falciparum, parasitaemia levels
between 250 and 100,000 asexual parasites/μl, no history
of anti-malarial use in the previous 14 days and no signs
of severe malaria or danger signs.
Treatment of patients and follow-up
After written informed consent was obtained, a detailed
medical history, clinical examination and both thick and
thin blood films were performed. Artesunate was admi-
nistered at a total dose of 16 mg/kg bw over seven days
(first day: 4 mg/kg bw; second to seventh days: 2 mg/kg
bw/day). Direct observed therapy (DOTS) was given for
seven days by the health worker. Tablets of artesunate
were obtained from the WHO (manufactured by Guilin
Pharmaceutical Co., Ltd., Guilin, China). In case of
vomiting within 30 minutes, the dose was repeated; if
vomiting occurred within 30 minutes after the repeated
dose, the patients were excluded from the study and re-
ferred for treatment at the healthcare facility.
Patients were followed up on days 1, 2, 3, 4, 5, 6, 7, 14,
21 and 28 for clinical and laboratory tests, which
included axillary temperature measurement and thick
blood smear preparation. If a patient could not be located
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the patient at his or her home. Patients who were not
located within one day of the expected visit were consid-
ered lost to follow-up and excluded from the study.
Sample size was calculated based on a predicted treat-
ment failure rate of 15% because the treatment failure
rate of artesunate in the area was unknown. At a confi-
dence level of 95% and a precision of approximately 5%,
a minimum of 50 patients were required for the drug to
be tested. At least 60 patients should be included to
allow up to 20% loss to follow-up and withdrawals dur-
ing the 28-day follow-up period.
Thick blood smears obtained on every visit day were
stained with 10% Giemsa for 10 minutes and examined
at 1,000× magnification by a trained microscopist to
confirm the species and parasite density. The parasite
density was determined by counting the number of asex-
ual forms and gametocytes in 200 leukocytes. Parasit-
aemia was estimated by assuming 6,000 leukocytes/μl. A
second microscopist blinded to the first result re-
examined the thick blood smear, and in case of discrep-
ancies greater than 50%, the smear was read by a third
microscopist. The geometric mean of the two closest
results was used as the parasitaemia value for each read-
ing. When the number of asexual parasites was less than
10 per 200 white blood cells in follow-up smears, count-
ing was performed in at least 500 white blood cells (ie,
to completion of the field in which the 500th white
blood cell was counted). A blood slide was considered
to be negative when examination of 1,000 white blood
cells revealed no asexual parasites. The presence of
gametocytes on an enrolment or follow-up slide was
noted, but this information did not contribute to the
basic evaluation.
Genotype analysis was conducted to differentiate re-
crudescence (same parasite strain) from newly acquired
infection (different parasite strain). This analysis is based
on the extensive genetic diversity among the malaria
parasite genes msp1, msp2 and glurp [18]. The genotypic
profiles of pre- and post-parasite strains are compared.
Outcome measures
Treatment efficacy and effectiveness were evaluated
among observed patients based on clinical and parasito-
logic outcomes and study endpoints in accordance with
WHO guidelines for in vivo efficacy monitoring [18].
The outcomes were classified as early treatment failure
(ETF), late clinical failure (LCF), late parasitological fail-
ure (LPF) and adequate clinical and parasitological re-
sponse (ACPR).
Ethical considerations
The study was reviewed and approved by the ethical
committee of the Chinese Centre for Disease Controland Prevention (China CDC). This study was also
registered at the website [19] under the number
ACTRN12610001008011.
Molecular marker analysis
DNA was extracted from dried blood samples on filter
papers using a QIAGEN mini kit and stored at −20°C
until future use. Nested PCR [8,14,19,20] was used to
amplify fragments of pfcrt, pfmdr1, pfdhfr, pfdhps and
pfatp6. Sequencing reactions were carried out using an
ABI PRISM BigDye Terminator v3.1 Cycle Sequencing
kit (Applied Biosystems, CA, USA) as specified by the
manufacturer. The sequences of the amplicons were




All of the patients were observed at the Rose Clinic
in Lazan City, a small town on the Myanmar side of
the border located 24°47′21.2200N and 97°33′21.0500 E
(Figure 1). The Rose Clinic is close to the town of
Nabang in Yingjiang County, China, and the two towns
are separated by the Lazan stream. The town of Myitkina
is located approximately 78 km north of Lazan City.
Patient characteristics
A total of 1,095 febrile patients were screened for mal-
aria by blood smear (microscopic examination). A total
of 302 malaria patients were found, including 153 cases
of P. vivax, 65 cases of P. falciparum malaria, four cases
of Plasmodium malariae and 11 cases of mixed infection
(Figure 2). All of the P. falciparum patients met the in-
clusion criteria.
Of the P. falciparum patients, 17 were female (26.2%)
and 48 were male (73.8%). The age distribution was 3.0%
under five years, 15.5% between five and 15 years and
81.5% >15 years. There was a mild predominance of
young adult males. All of the patients had a fever in the
48 hours preceding presentation to the clinic, and 73.8%
(48/65) exhibited an axillary temperature >37.5°C. The
geometric mean parasite density was 69,535 parasites/μl.
The probability of the patients with parasite on day 3 was
correlated with the parasite densities on day 0, that is,
the more parasite densities the more probability of posi-
tive on days 3 Table 1.
The patients’ ethnicity was also noted: 84% belonged
to the Jingpo ethnic group, which is dominant on both
sides of the border in this area; 13% were Bamar (Myan-
mar majority group); and the remaining 3% belonged to
the local Lisu ethnic group. Among the 7% who were
Chinese citizens, most were Han, and a few belonged to
the Jingpo group.
Figure 1 The location of Yingjiang County relative to neighbouring countries.
Huang et al. Malaria Journal 2012, 11:278 Page 4 of 8
http://www.malariajournal.com/content/11/1/278Clinical outcomes
Sixty-five patients were enrolled and received directly
observed anti-malarial treatment with artesunate (total
dose of 16 mg/kg over seven days); 10 withdrew from
the study, and six were lost to follow-up. The efficacy of
artesunate monotherapy was 95.9%.
All but two patients in the observed group demon-
strated adequate clinical and parasitological response.
The two patients with treatment failure were confirmed
to have new infection by PCR. The allelic variants of
msp1, msp2 and glurp were genotyped and the results of
the pre- and post-parasite strains of the two patients
were shown in Table 2.
Twelve patients had detectable parasitaemia on day 3.
The geometric mean parasite density on Day 0 in the
cases that were positive on day 3 was 89,519 asexual
parasites per μl, indicating a strong association between
day 3 positivity and high initial parasite density, as
observed in other studies. The lowest day 0 parasitaemia
associated with D3 positivity was 33,652 parasites/μl.
The average body temperature and parasite density of the
patients decreased dramatically on days 0, 1, 2, 3, 7, 14, 21
and 28 after seven days of artesunate treatment (Figure 3).
Molecular markers for drug resistance
Pfcrt and pfmdr1
A total of 63 samples were successfully amplified at posi-
tions 71, 72 and 76. Mutation in pfcrt codon 76 wasfound in all of the isolates (100%), and mutations in
codons 71 and 72 were found in 4.8% of parasite isolates.
No mutation in pfmdr1 (codons 86 or 1246) was found.Pfdhfr and pfdhps
The pfdhfr genes from 63 samples were successfully
amplified and compared with the wild-type sequence.
The frequencies of N51I, C59R, and I164L are shown in
Figure 4. The most prevalent mutations were C59R and
S108N, which were present in 92.1% and 90.6% of
patients, respectively (Table 3). The mixed infections in-
cluding quadruple (38.0%), triple (51.7) and double
mutants (10.3%) were described in Table 3.
For pfdhps, successful amplification was achieved in 59
samples, and mutations in codons 436, 437, 540 and 581
were found in all of the isolates (100%) including single,
double, triple or quadruple mutants. The A437G and
K540E mutants were most prevalent in pfdhps. Double
mutants in pfdhps were found in 57.6% of samples and
included 436/437, 436/540, 437/540, and 437/581
(Table 3). Except for one sample, all of the samples with
the K540E mutation also had the A437G mutation.Pfatp6
No mutation was found in pfatp6 codons 623 or 769,
but two new mutations (N683K and R756K) were found
in 4.6% and 9.2% of parasite isolates, respectively.
Figure 2 Patient recruitment and clinical outcomes.
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Artemisinin-based combination therapy is recommended
to slow the emergence and spread of drug resistance.
This effect is achieved by the use of anti-malarial drugs
with different mechanisms of action and the use of a
fast-acting highly effective anti-malarial drug, such as
DHA, in combination with a long-lasting anti-malarial
drug, such as piperaquine. China was the first country to
use artemisinin, and this drug was used for malaria
treatment in China for almost 20 years (from the 1990s
to 2007). In recent years, some reports confirmed arte-
misinin resistance in Southeast Asia, especially nearTable 1 Characteristics of patients with Plasmodium
falciparum
Total 65





History of fever (%) 100
Axillary temperature≥ 37.5˚C 73.8 (48/65)
Geometric mean parasite density (/μl) 69,535Thailand-Cambodia border areas, but the status of arte-
misinin in China was unclear. The spread of artemisinin
resistance from Cambodia to China or the de novo oc-
currence of artemisinin resistance in China is a serious
concern. This study was designed to evaluate clinical out-
come after seven-day artesunate monotherapy for un-
complicated P. falciparum malaria in Yingjiang County
along the China-Myanmar border and investigate the
prevalence of anti-malarial drug resistance markers. A
parallel study evaluating DHA-PIP was conducted simul-
taneously in another county, and the results of that study
will be published elsewhere.
Yunnan province is located in southern China, with a
population of approximately 30 million people in 129Table 2 The allele frequency of the pre- and post-
treatment of the two “treatment failure” patients
Sample PCR Product Size(s) (bp)
msp2 Glurp msp1
FC27 3D7/IC RO33 K1 MAD20
P1-D0 500 760 160
P1-D14 320 500 960 220
P2-D0 400 600 160
P2-D14 350 820 220
Figure 3 Average patient body temperature and parasite density on days 0, 1, 2, 3, 7, 14, 21 and 28 after artesunate treatment for
seven days.
Huang et al. Malaria Journal 2012, 11:278 Page 6 of 8
http://www.malariajournal.com/content/11/1/278counties. The province borders Myanmar, the Lao Peo-
ple’s Democratic Republic and Vietnam. The border with
Myanmar is 1,997 km long (as shown in Figure 1). Ying-
jiang County belongs to Dehong Prefecture with the total
population of 288,691 people, which has the highest mal-
aria incidence rate in China. The incidence in 2008 was
19.1 cases per 10,000, 38% of which were P. falciparum.
The majority of patients included in the study were
from Myanmar or had been infected in a region of
Myanmar close to the Chinese border. Among the 65
patients with P. falciparum, two had early treatment
failure (4.1%), ie, confirmed re-infection. Therefore, this
patient excluded as treatment failure with PCR correc-
tion until day 14. However, a key observation was the
high rate of parasite positivity on day 3. A total of
18.5% of the enrolled patients were parasite positive on
day 3. The initial parasite density was high, which mightFigure 4 Frequency of pfdhfr and pfdhps haplotypes in samples frompartially explain the high day 3 positivity rate, but the re-
sponse still suggested a lowered susceptibility to artesu-
nate, which was lower than the response rate observed
in western Cambodia in recent years. It is impossible to
say whether these findings reflect a spread from Cambo-
dia or local factors. Local factors include long-term ac-
cess to artemisinin (since at least the early or mid-
1990s) and highly irregular treatment schedules in an
area with continued moderate levels of transmission, as
suggested by the predominance of malaria in young
adults. Therefore, therapeutic efficacy tests should be
continued, and the containment of artemisinin resist-
ance in these areas should be prioritized.
Pfcrt and pfmdr1 genes have been proposed as mo-
lecular markers of chloroquine resistance, and they also
influence P. falciparum susceptibility to mefloquine,
quinine, halofantrine and artemisinin [21–23]. AccordingYingjiang County.
Table 3 Prevalence of pfdhfr (codons 51, 59, 108 and 164)
and pfdhps (codons 436, 437, 540 and 581) mutants
Gene Mutation Number Frequency (%)
pfdhfr Quadruple mutants 22 (58) 38.0
Triple mutants 51/59/108 9 (58) 15.5
Triple mutants 59/108/164 21 (58) 36.2
Double mutants 59/108 6 (58) 10.3
pfdhps Quadruple mutants 13 (55) 23.6
Triple mutants 436/437/581 8 (55) 14.5
Double mutants 436/437 2 (55) 3.6
Double mutants 436/540 1 (55) 1.8
Double mutants 437/540 28 (55) 50.9
Double mutants 437/581 3 (55) 5.5
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prevalence of mutation in codon 76 of pfcrt. As might be
expected from the previous studies on in vivo and
in vitro chloroquine responses in China [24], the isolates
of P. falciparum examined in the present study fre-
quently contained the pfcrt K76T mutation, especially in
Yunnan province. Although China has not used chloro-
quine to treat P. falciparum for over 30 years, the stable
and high prevalence of this mutation may be caused by
the continued use of chloroquine as a first-line drug for
P. vivax over several decades. Compared with the high
prevalence of pfcrt mutations, there was no mutation in
codons 86 or 1246 of pfmdr1 in any sample. This result
was consistent with other researchers’ findings [25-27].
Until now, the relationship between the Y86 mutation and
chloroquine resistance has not been confirmed, and there
have been many conflicting results. The results in this re-
search may indicate that P. falciparum in China is still sen-
sitive to mefloquine, quinine, halofantrine and artemisinin.
The effects of pfdhfr and pfdhps mutations on the mech-
anism of resistance to SP drugs have been well described.
Pyrimethamine was used for the radical treatment of P.
vivax in combination with primaquine 40 years ago [28].
Additionally, pyrimethamine was added to salt for prophy-
laxis in the 1980s [29]. Pyrimethamine plus primaquine
has always been recommended as prophylaxis for specific
populations in China [7] and sulphadoxine-
pyrimethamine were used in Myanmar in 1980’s and the
resistance at various levels were common throughout the
country in the beginning of 1990’s [30]. This study found
that the prevalence of quadruple, triple and double
mutants at the China-Myanmar border was high, which
suggested that these parasites are still resistant to anti-
folate anti-malarial drugs in China, two decades after SP
was abandoned as a first-line anti-malarial [31]. This re-
search also confirmed that the pfdhps A437G mutation
confers resistance to sulphadoxine and is often coupled
with the K540E mutant allele.The mechanism of action of artemisinin remains con-
troversial. One of its proposed mechanisms involves an
interaction with the sarcoplasmic reticulum Ca2+
ATPase6. The analysis of naturally occurring pfatp6
polymorphisms in field isolates suggested that a poly-
morphism at codon 769 may be associated with the
reduced susceptibility of these isolates to artemether
in vitro [17]. In line with other investigators, there was
any polymorphism in codons 263 or 769, which are
described as the key amino acids in the interaction be-
tween pfatp6 and artemisinins [32]. However, two new
mutations (N683K and R756K) were found in parasite
isolates in this study, and the mutation of position 683
has not been reported previously [33]. The mutations
observed in this study and in previous studies [34–36]
could be indirectly implicated in this interaction if they
are associated with artemisinin susceptibility. But one re-
cent study [37] on emergence of artemisinin-resistant
malaria on the western border of Thailand showed the
proportion of variation in parasite clearance attributable
to parasite genetics increased doubling compared with
year 2001–2004 and year 2007–2010. Considering the
development of artemisinin combination therapy and
the possible implication of pfatp6 in artemisinin resist-
ance, all of the polymorphisms in this gene should be
carefully monitored.
Conclusion
Slow parasite clearance and suspected artemisinin resist-
ance was observed in Yingjiang County at the China-
Myanmar border area, therefore it should be strengthen
further on parasite clearance time or clearance half life
to confirm the resistance status. And now Yunnan prov-
ince of China, as part of Greater Mekong Sub-region,
has already involved in “Greater Mekong Sub-region
Programme for Artemisinin Resistance Contain-
ment”, which will be launching this year or next year.
Also, this study provided basic data on artemisinin re-
sistance in this area, which will be helpful for other
countries in the Mekong sub-region. Moreover, molecu-
lar epidemiology should be continued as routine surveil-
lance and to provide complementary information to
assess the appropriateness of current policies based on
artemisinin derivatives.
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